Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Céleste Lebbé"'
Autor:
Céleste Lebbé, Armin Schueler, Richard Isaacs, Giorgio Massimini, Willem Kruit, Brigitte Dreno, Virginia Ferraresi, Caroline Robert, Luc Thomas, Enrique Espinosa, Carmen Loquai, Paul Vasey, Joseph Kerger, Bernard Guillot, Jean-Jacques Grob, Robert M. Conry, Caroline Dutriaux, Claus Garbe, Filippo de Braud, Thierry Lesimple
Publikováno v:
Cancers
Cancers, MDPI, 2020, 12 (7), pp.1727. ⟨10.3390/cancers12071727⟩
Cancers, 12(7):1727. Multidisciplinary Digital Publishing Institute (MDPI)
Cancers (Basel), 12 (7
Cancers, 2020, 12 (7), pp.1727. ⟨10.3390/cancers12071727⟩
Volume 12
Issue 7
Cancers, Vol 12, Iss 1727, p 1727 (2020)
Cancers, MDPI, 2020, 12 (7), pp.1727. ⟨10.3390/cancers12071727⟩
Cancers, 12(7):1727. Multidisciplinary Digital Publishing Institute (MDPI)
Cancers (Basel), 12 (7
Cancers, 2020, 12 (7), pp.1727. ⟨10.3390/cancers12071727⟩
Volume 12
Issue 7
Cancers, Vol 12, Iss 1727, p 1727 (2020)
This study investigated the efficacy and safety of pimasertib (MEK1/MEK2 inhibitor) versus dacarbazine (DTIC) in patients with untreated NRAS-mutated melanoma. Phase II, multicenter, open-label trial. Patients with unresectable, stage IIIc/IVM1 NRAS-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6beadf3f227784dd0a386688cda16602
https://hal.umontpellier.fr/hal-03256625
https://hal.umontpellier.fr/hal-03256625
Autor:
Vanna Chiarion-Sileni, Céleste Lebbé, Catriona M. McNeil, Joanna Pikiel, Jean-Jacques Grob, Luc Thomas, Lars Bastholt, Andrzej Mackiewicz, Michele Maio, Omid Hamid, Virginia Ferraresi, Marta Nyakas, Caroline Robert, Michelle Del Vecchio, Burcin Simsek, Michael Smylie, Laurent Mortier, Dirk Schadendorf, Carmen Loquai, Inge Marie Svane, Ana Arance, Gabriella Liszkay, Fareeda Hosein, Piotr Rutkowski, Paolo A. Ascierto, Florent Grange, Christoph Hoeller, Brigitte Dréno, Ralf Gutzmer, Claus Garbe
Publikováno v:
Journal for Immunotherapy of Cancer
Journal for Immunotherapy of Cancer, 2020, 8 (1), pp.e000391. ⟨10.1136/jitc-2019-000391⟩
Ascierto, P A, Del Vecchio, M, Mackiewicz, A, Robert, C, Chiarion-Sileni, V, Arance, A, Lebbé, C, Svane, I M, Mcneil, C, Rutkowski, P, Loquai, C, Mortier, L, Hamid, O, Bastholt, L, Dreno, B, Schadendorf, D, Garbe, C, Nyakas, M, Grob, J J, Thomas, L, Liszkay, G, Smylie, M, Hoeller, C, Ferraresi, V, Grange, F, Gutzmer, R, Pikiel, J, Hosein, F, Simsek, B & Maio, M 2020, ' Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma ', Journal for ImmunoTherapy of Cancer, vol. 8, no. 1, e000391 . https://doi.org/10.1136/jitc-2019-000391
Ascierto, P A, Del Vecchio, M, Mackiewicz, A, Robert, C, Chiarion-Sileni, V, Arance, A, Lebbé, C, Svane, I M, Mcneil, C, Rutkowski, P, Loquai, C, Mortier, L, Hamid, O, Bastholt, L, Dreno, B, Schadendorf, D, Garbe, C, Nyakas, M, Grob, J J, Thomas, L, Liszkay, G, Smylie, M, Hoeller, C, Ferraresi, V, Grange, F, Gutzmer, R, Pikiel, J, Hosein, F, Simsek, B & Maio, M 2020, ' Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma ', Journal for immunotherapy of cancer, vol. 8, no. 1, e000391 . https://doi.org/10.1136/jitc-2019-000391
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Journal for Immunotherapy of Cancer, 2020, 8 (1), pp.e000391. ⟨10.1136/jitc-2019-000391⟩
Ascierto, P A, Del Vecchio, M, Mackiewicz, A, Robert, C, Chiarion-Sileni, V, Arance, A, Lebbé, C, Svane, I M, Mcneil, C, Rutkowski, P, Loquai, C, Mortier, L, Hamid, O, Bastholt, L, Dreno, B, Schadendorf, D, Garbe, C, Nyakas, M, Grob, J J, Thomas, L, Liszkay, G, Smylie, M, Hoeller, C, Ferraresi, V, Grange, F, Gutzmer, R, Pikiel, J, Hosein, F, Simsek, B & Maio, M 2020, ' Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma ', Journal for ImmunoTherapy of Cancer, vol. 8, no. 1, e000391 . https://doi.org/10.1136/jitc-2019-000391
Ascierto, P A, Del Vecchio, M, Mackiewicz, A, Robert, C, Chiarion-Sileni, V, Arance, A, Lebbé, C, Svane, I M, Mcneil, C, Rutkowski, P, Loquai, C, Mortier, L, Hamid, O, Bastholt, L, Dreno, B, Schadendorf, D, Garbe, C, Nyakas, M, Grob, J J, Thomas, L, Liszkay, G, Smylie, M, Hoeller, C, Ferraresi, V, Grange, F, Gutzmer, R, Pikiel, J, Hosein, F, Simsek, B & Maio, M 2020, ' Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma ', Journal for immunotherapy of cancer, vol. 8, no. 1, e000391 . https://doi.org/10.1136/jitc-2019-000391
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
BackgroundWe have previously reported significantly longer overall survival (OS) with ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with advanced melanoma, with higher incidences of adverse events (AEs) at 10 mg/kg. This follow-up analysi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::510133352a63b0beb0ad853bb98c25db
https://www.ncbi.nlm.nih.gov/pubmed/32503946
https://www.ncbi.nlm.nih.gov/pubmed/32503946
Autor:
Céleste Lebbé, Merrick I. Ross, Axel Hauschild, Theodore F. Logan, Robert H.I. Andtbacka, John A. Glaspy, Philip Friedlander, Claus Garbe, Jason Chesney, Omid Hamid, Howard L. Kaufman, Parminder Singh, Jenny J. Kim, Frances A. Collichio, Jennifer Gansert, Mohammed M. Milhem, Lisa Chen, Igor Puzanov
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol 36, iss 17
Purpose We evaluated the combination of talimogene laherparepvec plus ipilimumab versus ipilimumab alone in patients with advanced melanoma in a phase II study. To our knowledge, this was the first randomized trial to evaluate addition of an oncolyti
Autor:
Piotr Rutkowski, Lars Bastholt, Ralf Gutzmer, Claus Garbe, Virginia Ferraresi, Marta Nyakas, Omid Hamid, Joanna Pikiel, Jean-Jacques Grob, Paolo A. Ascierto, Céleste Lebbé, Caroline Robert, Delphine Hennicken, Vanna Chiarion-Sileni, Michael Smylie, Gabriella Liszkay, Florent Grange, Catriona M. McNeil, Luc Thomas, Dirk Schadendorf, Andrzej Mackiewicz, Michele Del Vecchio, Christoph Hoeller, Carmen Loquai, Michele Maio, Inge Marie Svane, Anila Qureshi, Brigitte Dréno, Ana Arance, Laurent Mortier
Publikováno v:
Ascierto, P A, Del Vecchio, M, Robert, C, Mackiewicz, A, Chiarion-Sileni, V, Arance, A, Lebbe, C, Bastholt, L, Hamid, O, Rutkowski, P, McNeil, C, Garbe, C, Loquai, C, Dreno, B, Thomas, L, Grob, J-J, Liszkay, G, Nyakas, M, Gutzmer, R, Pikiel, J, Grange, F, Hoeller, C, Ferraresi, V, Smylie, M, Schadendorf, D, Mortier, L, Svane, I M, Hennicken, D, Qureshi, A & Maio, M 2017, ' Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma : a randomised, double-blind, multicentre, phase 3 trial ', Lancet Oncology, vol. 18, no. 5, pp. 611-622 . https://doi.org/10.1016/S1470-2045(17)30231-0
Articles Lancet Oncol
Articles Lancet Oncol, 2017, 18 (5), pp.611-622. 〈10.1016/S1470-2045(17)30231-0〉
Lancet Oncology
Lancet Oncology, 2017, 18 (5), pp.611-622. ⟨10.1016/S1470-2045(17)30231-0⟩
Lancet Oncology, Elsevier, 2017, 18 (5), pp.611-622. ⟨10.1016/S1470-2045(17)30231-0⟩
Articles Lancet Oncol
Articles Lancet Oncol, 2017, 18 (5), pp.611-622. 〈10.1016/S1470-2045(17)30231-0〉
Lancet Oncology
Lancet Oncology, 2017, 18 (5), pp.611-622. ⟨10.1016/S1470-2045(17)30231-0⟩
Lancet Oncology, Elsevier, 2017, 18 (5), pp.611-622. ⟨10.1016/S1470-2045(17)30231-0⟩
BACKGROUND: A phase 2 trial suggested increased overall survival and increased incidence of treatment-related grade 3-4 adverse events with ipilimumab 10 mg/kg compared with ipilimumab 3 mg/kg in patients with advanced melanoma. We report a phase 3 t
Autor:
Mazhar Ajaz, Laurent Mortier, Inge Marie Svane, Ivan Marquez-Rodas, Thomas Eigentler, Jennifer Lord-Bessen, Paolo A. Ascierto, Elena Grigoryeva, Dirk Schadendorf, Caroline Robert, Linda Rollin, Jacopo Pigozzo, Nicolas Meyer, Michael Smylie, Rene Gonzalez, Alexander M. Menzies, Piotr Rutkowski, Céleste Lebbé, Abdel Saci
Publikováno v:
Journal of Clinical Oncology
Lebbé, C, Meyer, N, Mortier, L, Marquez-Rodas, I, Robert, C, Rutkowski, P, Menzies, A M, Eigentler, T, Ascierto, P A, Smylie, M, Schadendorf, D, Ajaz, M, Svane, I M, Gonzalez, R, Rollin, L, Lord-Bessen, J, Saci, A, Grigoryeva, E & Pigozzo, J 2019, ' Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma : Results From the Phase IIIb/IV CheckMate 511 Trial ', Journal of Clinical Oncology, vol. 37, no. 11, pp. 867-875 . https://doi.org/10.1200/JCO.18.01998
Lebbé, C, Meyer, N, Mortier, L, Marquez-Rodas, I, Robert, C, Rutkowski, P, Menzies, A M, Eigentler, T, Ascierto, P A, Smylie, M, Schadendorf, D, Ajaz, M, Svane, I M, Gonzalez, R, Rollin, L, Lord-Bessen, J, Saci, A, Grigoryeva, E & Pigozzo, J 2019, ' Evaluation of Two Dosing Regimens for Nivolumab in Combination With Ipilimumab in Patients With Advanced Melanoma : Results From the Phase IIIb/IV CheckMate 511 Trial ', Journal of Clinical Oncology, vol. 37, no. 11, pp. 867-875 . https://doi.org/10.1200/JCO.18.01998
PURPOSE Nivolumab 1 mg/kg plus ipilimumab 3 mg/kg (NIVO1+IPI3) is approved for first-line treatment of patients with advanced melanoma in several countries. We conducted a phase IIIb/IV study (CheckMate 511) to determine if nivolumab 3 mg/kg plus ipi
Publikováno v:
Melanoma Research. 24:237-243
In a previous large randomized, open-label study, retrospective subset analysis revealed that the addition of the Bcl-2 antisense oligonucleotide oblimersen to dacarbazine (Dac) significantly improved overall survival, progression-free survival, and
Autor:
Alexander M.M. Eggermont, Stefan Suciu, Jessica C. Hassel, Saad Tahir, Michael Smylie, Virginia Ferraresi, F. Stephen Hodi, Jon M. Richards, Jean-Jacques Grob, Gaetan de Schaetzen, Michele Maio, Lars Bastholt, Céleste Lebbé, Luc Thomas, Jeffrey S. Weber, Corina Taitt, Jedd D. Wolchok, Alessandro Testori, Omid Hamid, Reinhard Dummer, Vanna Chiarion-Sileni, Veerle de Pril, Caroline Robert, Laurent Mortier, Axel Hauschild, Paolo A. Ascierto, Henrik Schmidt
Publikováno v:
Eggermont, A M M, Chiarion-Sileni, V, Grob, J-J, Dummer, R, Wolchok, J D, Schmidt, H, Hamid, O, Robert, C, Ascierto, P A, Richards, J M, Lebbé, C, Ferraresi, V, Smylie, M, Weber, J S, Maio, M, Bastholt, L, Mortier, L, Thomas, L, Tahir, S, Hauschild, A, Hassel, J C, Hodi, F S, Taitt, C, de Pril, V, de Schaetzen, G, Suciu, S & Testori, A 2016, ' Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy ', The New England Journal of Medicine, vol. 375, no. 19, pp. 1845-1855 . https://doi.org/10.1056/NEJMoa1611299
BACKGROUND: On the basis of data from a phase 2 trial that compared the checkpoint inhibitor ipilimumab at doses of 0.3 mg, 3 mg, and 10 mg per kilogram of body weight in patients with advanced melanoma, this phase 3 trial evaluated ipilimumab at a d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80e78ee5b514ba66d939ec946d41104c
https://pure.au.dk/portal/da/publications/prolonged-survival-in-stage-iii-melanoma-with-ipilimumab-adjuvant-therapy(0df58c2a-4640-459d-be0c-75fa394c3bcb).html
https://pure.au.dk/portal/da/publications/prolonged-survival-in-stage-iii-melanoma-with-ipilimumab-adjuvant-therapy(0df58c2a-4640-459d-be0c-75fa394c3bcb).html